Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01923298 · ADVERSE EVENTS

Adverse events

Estradiol Levels in Patients Treated With Estring · Source last updated 2022-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed through study completion.
Other-event reporting threshold
0%

All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed through study completion.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Estradiol

ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.

0 / 00 / 00 / 0

Group identifiers: EG000: Estradiol

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed through study completion.
      event Groups
      1. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Estradiol
      frequency Threshold
      0
      time Frame
      All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed through study completion.

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice